Journal of Hypertension · 2012 · 44 citations · 22 references
MedicineEndocrinologyPharmacologyClinical BiochemistryNeuropharmacologySleep MedicineCannabinoid PharmacologyDiabetes MellitusInsulin ResistanceSleep PhysiologySleep-disordered BreathingSleep-related Breathing DisordersEndocannabinoid MetabolismEndocannabinoid SignalingEndocannabinoid SystemImpaired Insulin SensitivitySleep Apnea SyndromeSympathetic Nervous System Responses
OBJECTIVE: Obstructive sleep apnea chronically increases blood pressure through sympathetic nervous system activation. In animals, hypertension and sympathetic activity are restrained by cannabinoid receptor activation. Therefore, we hypothesized that increased blood pressure in patients with obstructive sleep apnea is associated with increased circulating endocannabinoid concentrations. METHODS: Arterial oxygen saturation and apnea/hypopnea episodes were recorded in 29 patients with normal glucose tolerance, 26 patients with type 2 diabetes mellitus, and 21 patients obese subjects without sleep apnea. We determined seated blood pressure, insulin, glucose, and high-sensitive C-reactive protein in the morning, and insulin sensitivity by euglycemic-hyperinsulinemic clamp the next day. Anandamide, the sum of 1-arachidonoylglycerol and 2-arachidonoylglycerol, and oleoylethanolamide were measured in plasma by liquid chromatography-tandem mass spectrometry. RESULTS: Endocannabinoid concentrations in sleep apnea patients were increased compared to obese individuals without disordered nocturnal breathing. Correction for variables of obesity and insulin resistance almost completely abrogated this difference in endocannabinoids. Anandamide strongly correlated with blood pressure in sleep apnea patients (r = 0.60 for SBP and r = 0.58 for DBP, P < 0.001). In multivariate regression analysis, anandamide was a stronger determinant of blood pressure than sleep apnea severity, obesity, insulin resistance, and inflammation. CONCLUSION: Obstructive sleep apnea patients show positive correlations between blood pressure and venous anandamide concentrations independent of confounding factors. Our data suggest a previously not recognized role of the endocannabinoid system for blood pressure regulation in patients with high risk for hypertension and cardiovascular disease.
22
Plasma Visfatin Concentrations and Fat Depot–Specific mRNA Expression in Humans
Janin Berndt, Nora Klöting, Susan Kralisch et al. · Diabetes · 2005 · 720 citations · Full text
Activation of the Peripheral Endocannabinoid System in Human Obesity
Stefan Engeli, Jana Böhnke, M Feldpausch et al. · Diabetes · 2005 · 690 citations · Full text
Isabel Matias, Marie‐Paule Gonthier, Pierangelo Orlando et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 651 citations
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Matthias Blüher, Stefan Engeli, Nora Klöting et al. · Diabetes · 2006 · 528 citations · Full text